PT  - JOURNAL ARTICLE
AU  - Li, Qianxia
AU  - Huang, Chiang-Ching
AU  - Huang, Shane
AU  - Tian, Yijun
AU  - Huang, Jinyong
AU  - Bitaraf, Amirreza
AU  - Dong, Xiaowei
AU  - Nevalanen, Marja T.
AU  - Patel, Manishkumar
AU  - Wong, Jodie
AU  - Zhang, Jingsong
AU  - Manley, Brandon J.
AU  - Park, Jong Y.
AU  - Kohli, Manish
AU  - Gore, Elizabeth M.
AU  - Kilari, Deepak
AU  - Wang, Liang
TI  - 5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapies
AID  - 10.1101/2023.10.13.23296758
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2023.10.13.23296758
4099  - http://medrxiv.org/content/early/2024/10/17/2023.10.13.23296758.short
4100  - http://medrxiv.org/content/early/2024/10/17/2023.10.13.23296758.full
AB  - Background Currently, no biomarkers are available to identify resistance to androgen-deprivation therapies (ADT) in men with hormone-naive prostate cancer. Since 5-hydroxymethylcytosines (5hmC) in gene body are associated with gene activation, in this study, we evaluated whether 5hmC signatures in cell-free DNA (cfDNA) predicts early resistance to ADT.Results We collected a total of 139 serial plasma samples from 55 prostate cancer patients receiving ADT at three time points including baseline (prior to initiating ADT, N=55), 3-month (after initiating ADT, N=55), and disease progression (N=15) within 24 months or 24-month if no progression was detected (N=14). To quantify 5hmC abundance across the genome, we used selective chemical labeling sequencing and mapped sequence reads to individual genes. Differential methylation analysis in baseline samples identified significant 5hmC difference in 1,642 of 23,433 genes between patients with and without progression (false discovery rate, FDR<0.1). Patients with disease progression showed significant 5hmC enrichments in multiple hallmark gene sets with androgen responses as top enriched gene set (FDR=1.19E-13). Interestingly, this enrichment was driven by a subgroup of patients featuring a significant 5hmC hypermethylation in the gene sets involving AR, FOXA1 and GRHL2. To quantify overall activities of these gene sets, we developed a gene set activity scoring algorithm and observed significant association of high activity scores with poor progression-free survival (P<0.05). Longitudinal analysis showed that the high activity scores were significantly reduced after 3-months of initiating ADT (P<0.0001) but returned to higher levels when the disease was progressed (P<0.05).Conclusions This study demonstrates that 5hmC-based activity scores from gene sets involved in AR, FOXA1 and GRHL2 may be used as biomarkers to determine early treatment resistance, monitor disease progression, and potentially identify patients who would benefit from upfront treatment intensification.Competing Interest StatementThe authors declare no conflict of interest.Funding StatementThis study was funded by National Institute of Health (R01CA212097 and R01CA250018 to LW).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institute review boards of Medical College of Wisconsin, Milwaukee VA Medical Center and Moffitt Cancer Center gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.ADTAndrogen Deprivation TherapyFDRFalse Discovery RateARAndrogen ReceptorFOXA1Forkhead Box A1GRHL2Grainyhead Like Transcription Factor 2PSAProstate Specific AntigenARSIAndrogen Receptor Signaling InhibitorcfDNAcell-free DNA5hmC5-hydroxymethylcytosinesVAVeteran AffairNCCNNational Comprehensive Cancer NetworkECOGEastern Cooperative Oncology GroupGSEAGene Set Enrichment AnalysisANCOVAAnalysis of CovarianceDMGsDifferentially Methylated GenesCDSCoding SequenceChIPChromatin ImmunoprecipitationLHRHLuteinizing Hormone-Releasing Hormone